Methods	Single centre RCT. Study duration: 09/2003 to 09/2006. Follow-up: 1 year.
Participants	Low-risk GTN. Number eligible:131. Number evaluable:131. Participants randomised into two groups: group 1 = 81 and group 2 = 50 (randomisation ratio of 1.5 MTX:1 DACT applied). Reasons given for this were economic limitations Excluded patients with choriocarcinoma.
Interventions
Outcomes
Notes	Risk scoring: FIGO 2000. Six women ( 4 in group 1 and 2 in group 2) did not complete their first-line chemotherapy, but were considered in the ITT analysis
Risk of bias
Bias	Authors’ judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Sequence generation not described.
Allocation concealment (selection bias)	Unclear risk	Allocation concealment not described.
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Blinding not described.
Incomplete outcome data (attrition bias) All outcomes	Low risk	100% of randomised participants were analysed.
Selective reporting (reporting bias)	Low risk	All pre-specified and expected outcomes were reported. Analysis was by ITT
Other bias	Unclear risk	See ‘Risk of bias’ comment for Gilani 2005.

Abbreviations: CR = Complete response; CT = chemotherapy; DACT = Dactinomycin or Actinomycin D; FIGO = International Federation of Gynecology and Obstetrics; GOG = Gynecologic Oncology Group; GTN = Gestational trophoblastic neoplasia; hCG = human chorionic gonadotrophin; IM = intramuscular; ITT = Intention-to-treat; IV = intravenous; MTX = Methotrexate; MTX-FA = methotrexate-folinic acid; RCT = randomised controlled trial